Evaluating the effect of Losartan on pancreatic cancer
Clinical Study Evaluating the Effect of Losartan on Response Rate in Both Metastatic and Locally Advanced Pancreatic Cancer Patients
This study is testing if the blood pressure medication Losartan can help older patients with pancreatic cancer live better and longer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 50 Years to 85 Years |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Tanta) |
| Trial ID | NCT06539806 on ClinicalTrials.gov |
What this trial studies
This clinical study investigates the impact of Losartan, a medication typically used for hypertension, on patients diagnosed with pancreatic cancer. The study focuses on individuals aged 50 and older who have confirmed metastatic or locally advanced pancreatic adenocarcinoma and are also hypertensive. Participants will receive a dosage of 50mg of Losartan, and the study aims to assess its potential effects on cancer progression and patient outcomes. The research is grounded in the understanding that components of the renin-angiotensin system may play a role in the development and progression of pancreatic cancer.
Who should consider this trial
Good fit: Ideal candidates for this study are male and female patients aged 50 and older with histologically confirmed metastatic or locally advanced pancreatic adenocarcinoma and hypertension.
Not a fit: Patients with serious concomitant systemic disorders, active autoimmune diseases, or those who have had prior severe reactions to specific cancer therapies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new therapeutic approach for managing pancreatic cancer in hypertensive patients.
How similar studies have performed: While the role of the renin-angiotensin system in cancer is being explored, this specific approach using Losartan in pancreatic cancer is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and female pancreatic cancer patients aged ≥ 50 years old. * Hypertensive patient with BP ≥ 140/90 mm Hg. * Histologically confirmed metastatic pancreatic adenocarcinoma; or locally advanced pancreatic cancer patients. * All included patients must sign an informed consent Exclusion Criteria: * Patients with serious concomitant systemic disorders as significant cardiac, renal, hepatic, or pulmonary morbidity. * Pregnant or lactating women and women of childbearing potential. * Patients received prior systemic fluoropyrimidine therapy within the past 10 years. * Prior un-anticipated severe reaction to fluoropyrimidine therapy, or known hypersensitivity to 5-fluorouracil, irinotecan, oxaliplatin, losartan, or any monoclonal antibody. * Patients with an active, known, or suspected autoimmune disease such as psoriasis. * Patients with a known positive test for hepatitis B virus surface antigen (HBV s Ag) or hepatitis C virus (HCV antibody) and patients with a known history of testing positive for (HIV) or known acquired immunodeficiency syndrome (AIDS). * Patients received a live vaccine or live attenuated vaccines as intranasal influenza vaccines within 30 days of the planned start of study therapy.
Where this trial is running
Tanta
- Tanta University Hospital — Tanta, Egypt (Recruiting)
Study contacts
- Study coordinator: Mona Abd El-Rafea Mohamed, M.D
- Email: drmona.abdo14@gmail.com
- Phone: +201150232022
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.